Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
nab-paclitaxel + gemcitabine + anti-diabetics
- Development stage
- Unknown
- Lead developer
- Bristol Myers Squibb
- Modality
- Small Molecules, Recombinant Proteins and Enzymes, Nanoparticles → Drug Delivery Systems
- Administration
- Intravenous, Oral, Subcutaneous
01
Overview
This therapeutic regimen, currently under investigation by Fudan University, combines the standard-of-care chemotherapy doublet of nab-paclitaxel and gemcitabine with active anti-diabetic management (including metformin, insulin, or other glucose-lowering agents) for patients with metastatic pancreatic cancer and concurrent type 3c diabetes mellitus. The approach aims to evaluate whether optimized glycemic control and the potential synergistic anti-tumor properties of certain anti-diabetic medications can improve clinical outcomes, specifically overall survival, in this patient subset. Nab-paclitaxel acts as a microtubule stabilizer, gemcitabine functions as a nucleoside analog that inhibits DNA synthesis, and the anti-diabetic components target metabolic pathways to manage secondary diabetes and potentially inhibit cancer cell metabolism through mechanisms such as AMPK activation.
- Other names
- Active Anti-diabetic Treatment Plus Chemotherapy
02
Targets
CDA (Cytidine deaminase)DNAAMPK (Adenosine monophosphate–activated protein kinase)INSR (Insulin receptor)TUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on nab-paclitaxel + gemcitabine + anti-diabetics.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on nab-paclitaxel + gemcitabine + anti-diabetics.